Alkem launches pertuzumab biosimilar ‘Pertuza’ for treatment of HER2-positive breast cancer

Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab

Alkem launches ceramide-boosting moisturizing lotion for skin barrier repair

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure

Alkem launches Kojiglo serum to manage facial hyperpigmentation

This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology

Alkem enters into licensing agreement with BioTherapeutics

Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings

Alkem denies claims of Pan-D, Clavam 625 batches being substandard quality

The samples of both products mentioned in the CDSCO list are spurious and not manufactured by Alkem

Alkem signs license agreement with Takeda to commercialise Vonoprazan in India

Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)

Alkem healthy lungs initiative to promote importance of inhalation therapy

The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases

Briefs: Alkem and Krsnaa Diagnostics

Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.